Venture Capital Funding in US Biotech Firms
Venture capital funding in US biotech firms remains a defining force behind therapeutic innovation, platform development, and early-stage commercialization strategy. While public markets fluctuate, private capital continues to shape how emerging biotechnology companies structure pipelines, manage regulatory risk, and position for acquisition or IPO. The funding environment reflects a recalibration toward disciplined science, differentiated assets, … Read more